» Articles » PMID: 35046787

A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions

Overview
Specialty Biology
Date 2022 Jan 20
PMID 35046787
Authors
Affiliations
Soon will be listed here.
Abstract

In order to understand the link between substantia nigra pars compacta (SNc) cell loss and Parkinson's disease (PD) symptoms, we developed a multiscale computational model that can replicate the symptoms at the behavioural level by incorporating the key cellular and molecular mechanisms underlying PD pathology. There is a modelling tradition that links dopamine to reward and uses reinforcement learning (RL) concepts to model the basal ganglia. In our model, we replace the abstract representations of reward with the realistic variable of extracellular DA released by a network of SNc cells and incorporate it in the RL-based behavioural model, which simulates the arm reaching task. Our results successfully replicated the impact of SNc cell loss and levodopa (L-DOPA) medication on reaching performance. It also shows the side effects of medication, such as wearing off and peak dosage dyskinesias. The model demonstrates how differential dopaminergic axonal degeneration in basal ganglia results in various cardinal symptoms of PD. It was able to predict the optimum L-DOPA medication dosage for varying degrees of cell loss. The proposed model has a potential clinical application where drug dosage can be optimised as per patient characteristics.

Citing Articles

A Basal Ganglia model for understanding working memory functions in healthy and Parkinson's conditions.

Vigneswaran C, Nair S, Chakravarthy V Cogn Neurodyn. 2024; 18(4):1913-1929.

PMID: 39104688 PMC: 11297868. DOI: 10.1007/s11571-023-10056-y.


A Computational Model of Deep Brain Stimulation for Parkinson's Disease Tremor and Bradykinesia.

Nair S, Chakravarthy S Brain Sci. 2024; 14(6).

PMID: 38928620 PMC: 11201485. DOI: 10.3390/brainsci14060620.


A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.

Muddapu V, Vijayakumar K, Ramakrishnan K, Chakravarthy V Front Neurosci. 2022; 16:797127.

PMID: 35516806 PMC: 9063169. DOI: 10.3389/fnins.2022.797127.

References
1.
Fahn S . Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol. 2005; 252 Suppl 4:IV37-IV42. DOI: 10.1007/s00415-005-4008-5. View

2.
Muddapu V, Chakravarthy V . A Multi-Scale Computational Model of Excitotoxic Loss of Dopaminergic Cells in Parkinson's Disease. Front Neuroinform. 2020; 14:34. PMC: 7555610. DOI: 10.3389/fninf.2020.00034. View

3.
Gonzalez-Rodriguez P, Zampese E, Surmeier D . Selective neuronal vulnerability in Parkinson's disease. Prog Brain Res. 2020; 252:61-89. DOI: 10.1016/bs.pbr.2020.02.005. View

4.
Schultz W . Predictive reward signal of dopamine neurons. J Neurophysiol. 1998; 80(1):1-27. DOI: 10.1152/jn.1998.80.1.1. View

5.
Nambu A, Tokuno H, Takada M . Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res. 2002; 43(2):111-7. DOI: 10.1016/s0168-0102(02)00027-5. View